miércoles, 11 de noviembre de 2009

Call for Public Review: Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment



Secondary Lymphedema Review Period Announcement
The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment Program will be posting a draft technology assessment for review on November 18, 2009.
This draft is entitled, “Diagnosis and Treatment of Secondary Lymphedema.” If you are interested in reviewing this document, please visit: http://www.ahrq.gov/clinic/ta/tareview.htm. The document will be available for review from 9:00 AM on November 18, 2009 to 5:00 PM December 8, 2009.

Call for Public Review
Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment

-------------------
The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment (TA) Program develops systematic reviews, health technology assessments, and other reports at the request of the Centers for Medicare & Medicaid Services (CMS) Coverage and Analysis Group. These reports are funded by an Interagency Agreement from CMS to AHRQ and used to inform national coverage policies, discussion at public Medicare Evidence Development and Coverage Advisory Committee (MedCAC) meetings, and/or for other policy considerations.

To get complete public review, the AHRQ TA Program will post draft reports on the AHRQ TA Web site. To meet the timelines for Medicare coverage decisions mandated by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, draft technology assessment reports will be available for public review for a limited time. A notice will be sent out on the CMS Medicare Coverage and AHRQ Effective Health Care E-mail distribution lists 1 week before the posting of draft reports. Each report will be available for public review on this Web site for a total of 2 weeks.

AHRQ's TA Program supports and is committed to the transparency of its review process. Therefore, starting March 18, 2009, invited peer review comments and public review comments will be publicly posted on the TA Program Web site at http://www.ahrq.gov/clinic/techix.htm within 3 months after the associated final report is posted on this Web site. The report authors' responses to the comments (the "disposition of comments") will be posted on the same Web page as the associated comments.


------------
Review Steps
When a draft Technology Assessment report is available for review, you may review the draft report by completing the associated review form and then selecting "Submit" on the form.

Note: Comments received after the review period will not be accepted.

Currently Available for Review
Technology Assessment: Report on the Evidence Regarding Off-Label Indications for Targeted Therapies used in Cancer Treatment (PDF file, 4.2 MB; PDF Help)
Date Available: 9:00 AM October 26 - 5:00 PM November 16.
en htlm:
http://www.ahrq.gov/clinic/ta/targthrps/

en PDF (428 páginas):
http://www.ahrq.gov/clinic/ta/targthrps/targthrps.pdf
Note: Due to a delay in the distribution of the review announcement to the TA Program E-mail list, the review period for the technology assessment draft on targeted therapies for cancer will be extended until November 16, 2009.

If you have any problems with your submission, please E-mail your comments along with a statement indicating your acceptance of the AHRQ Technology Assessment Program Public Review disclosure policy to tareview@ahrq.hhs.gov. Thank you.

abrir aquí para acceder al documento AHRQ completo:
Call for Public Review

No hay comentarios:

Publicar un comentario